il 17 ifn γ  (R&D Systems)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Name:
    Recombinant Human IFN alpha I alpha 17 Protein
    Description:
    The Recombinant Human IFN alpha I alpha 17 Protein from R D Systems is derived from E coli The Recombinant Human IFN alpha I alpha 17 Protein has been validated for the following applications Bioactivity
    Catalog Number:
    11150-1
    Price:
    299
    Category:
    Proteins and Enzymes
    Source:
    E. coli-derived Recombinant Human IFN-alpha I (alpha 17) Protein
    Applications:
    Bioactivity
    Purity:
    >95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie« Blue stain.
    Conjugate:
    Unconjugated
    Size:
    100000 UN
    Buy from Supplier


    Structured Review

    R&D Systems il 17 ifn γ
    Expression of surface markers on monocytes stimulated with <t>IL-17.</t> Human CD14 ++ CD16 − and CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TLR4, (e) CD86, and (i) HLA-DR. Human CD14 ++ CD16 − in post-STEMI: (b) TLR4, (f) CD86, and (j) HLA-DR. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (c) TLR4, (g) CD86, and (k) HLA-DR. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (d) TLR4, (h) CD86, and (l) HLA-DR. Expression levels of TLR4, CD86, and HLA-DR are expressed as MFI. White column: STEMI; black column: post-STEMI; n = 11. ∗ p
    The Recombinant Human IFN alpha I alpha 17 Protein from R D Systems is derived from E coli The Recombinant Human IFN alpha I alpha 17 Protein has been validated for the following applications Bioactivity
    https://www.bioz.com/result/il 17 ifn γ/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    il 17 ifn γ - by Bioz Stars, 2021-06
    94/100 stars

    Images

    1) Product Images from "Effect of Interleukin-17 in the Activation of Monocyte Subsets in Patients with ST-Segment Elevation Myocardial Infarction"

    Article Title: Effect of Interleukin-17 in the Activation of Monocyte Subsets in Patients with ST-Segment Elevation Myocardial Infarction

    Journal: Journal of Immunology Research

    doi: 10.1155/2020/5692829

    Expression of surface markers on monocytes stimulated with IL-17. Human CD14 ++ CD16 − and CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TLR4, (e) CD86, and (i) HLA-DR. Human CD14 ++ CD16 − in post-STEMI: (b) TLR4, (f) CD86, and (j) HLA-DR. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (c) TLR4, (g) CD86, and (k) HLA-DR. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (d) TLR4, (h) CD86, and (l) HLA-DR. Expression levels of TLR4, CD86, and HLA-DR are expressed as MFI. White column: STEMI; black column: post-STEMI; n = 11. ∗ p
    Figure Legend Snippet: Expression of surface markers on monocytes stimulated with IL-17. Human CD14 ++ CD16 − and CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TLR4, (e) CD86, and (i) HLA-DR. Human CD14 ++ CD16 − in post-STEMI: (b) TLR4, (f) CD86, and (j) HLA-DR. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (c) TLR4, (g) CD86, and (k) HLA-DR. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (d) TLR4, (h) CD86, and (l) HLA-DR. Expression levels of TLR4, CD86, and HLA-DR are expressed as MFI. White column: STEMI; black column: post-STEMI; n = 11. ∗ p

    Techniques Used: Expressing, Positive Control, Negative Control

    IL-17 induces the secretion of proinflammatory cytokines in monocyte subsets. Human CD14 ++ CD16 − or CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TNF- α and (c) IL-6. Human CD14 ++ CD16 − in post-STEMI: (b) TNF- α and (d) IL-6. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (e) TNF- α and (g) IL-6. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (f) TNF- α and (h) IL-6. Concentrations of TNF- α and IL-6 in the culture supernatants were determined by ELISA. White column: STEMI; black column: post-STEMI; n = 11. ∗ p
    Figure Legend Snippet: IL-17 induces the secretion of proinflammatory cytokines in monocyte subsets. Human CD14 ++ CD16 − or CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TNF- α and (c) IL-6. Human CD14 ++ CD16 − in post-STEMI: (b) TNF- α and (d) IL-6. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (e) TNF- α and (g) IL-6. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (f) TNF- α and (h) IL-6. Concentrations of TNF- α and IL-6 in the culture supernatants were determined by ELISA. White column: STEMI; black column: post-STEMI; n = 11. ∗ p

    Techniques Used: Positive Control, Negative Control, Enzyme-linked Immunosorbent Assay

    Monocytes transmigrate across a human umbilical vein endothelial cell monolayer in response to IL-17. A sample of 3 × 10 5 (a–c) CD14 ++ CD16 − or (d–f) CD14 ++ CD16 + /CD14 + CD16 ++ monocytes was added to the upper surface of monolayers of human umbilical vein endothelial cells (HUVECs) previously treated with IL-17, IFN- γ , or IL-17/IFN- γ ; culture medium alone was used as a negative control. The monocytes were allowed to transmigrate across the HUVEC monolayers in the presence of CCL2, CX3CL1, or culture medium for 3 hours. All data are presented as the migration index, which relates the number of cells that migrated in response to the indicated stimulus to the number of cells that migrated in response to the negative control. White column: STEMI: black column: post-STEMI; n = 11. ∗ p
    Figure Legend Snippet: Monocytes transmigrate across a human umbilical vein endothelial cell monolayer in response to IL-17. A sample of 3 × 10 5 (a–c) CD14 ++ CD16 − or (d–f) CD14 ++ CD16 + /CD14 + CD16 ++ monocytes was added to the upper surface of monolayers of human umbilical vein endothelial cells (HUVECs) previously treated with IL-17, IFN- γ , or IL-17/IFN- γ ; culture medium alone was used as a negative control. The monocytes were allowed to transmigrate across the HUVEC monolayers in the presence of CCL2, CX3CL1, or culture medium for 3 hours. All data are presented as the migration index, which relates the number of cells that migrated in response to the indicated stimulus to the number of cells that migrated in response to the negative control. White column: STEMI: black column: post-STEMI; n = 11. ∗ p

    Techniques Used: Negative Control, Migration

    2) Product Images from "Effect of Interleukin-17 in the Activation of Monocyte Subsets in Patients with ST-Segment Elevation Myocardial Infarction"

    Article Title: Effect of Interleukin-17 in the Activation of Monocyte Subsets in Patients with ST-Segment Elevation Myocardial Infarction

    Journal: Journal of Immunology Research

    doi: 10.1155/2020/5692829

    Expression of surface markers on monocytes stimulated with IL-17. Human CD14 ++ CD16 − and CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TLR4, (e) CD86, and (i) HLA-DR. Human CD14 ++ CD16 − in post-STEMI: (b) TLR4, (f) CD86, and (j) HLA-DR. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (c) TLR4, (g) CD86, and (k) HLA-DR. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (d) TLR4, (h) CD86, and (l) HLA-DR. Expression levels of TLR4, CD86, and HLA-DR are expressed as MFI. White column: STEMI; black column: post-STEMI; n = 11. ∗ p
    Figure Legend Snippet: Expression of surface markers on monocytes stimulated with IL-17. Human CD14 ++ CD16 − and CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TLR4, (e) CD86, and (i) HLA-DR. Human CD14 ++ CD16 − in post-STEMI: (b) TLR4, (f) CD86, and (j) HLA-DR. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (c) TLR4, (g) CD86, and (k) HLA-DR. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (d) TLR4, (h) CD86, and (l) HLA-DR. Expression levels of TLR4, CD86, and HLA-DR are expressed as MFI. White column: STEMI; black column: post-STEMI; n = 11. ∗ p

    Techniques Used: Expressing, Positive Control, Negative Control

    IL-17 induces the secretion of proinflammatory cytokines in monocyte subsets. Human CD14 ++ CD16 − or CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TNF- α and (c) IL-6. Human CD14 ++ CD16 − in post-STEMI: (b) TNF- α and (d) IL-6. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (e) TNF- α and (g) IL-6. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (f) TNF- α and (h) IL-6. Concentrations of TNF- α and IL-6 in the culture supernatants were determined by ELISA. White column: STEMI; black column: post-STEMI; n = 11. ∗ p
    Figure Legend Snippet: IL-17 induces the secretion of proinflammatory cytokines in monocyte subsets. Human CD14 ++ CD16 − or CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TNF- α and (c) IL-6. Human CD14 ++ CD16 − in post-STEMI: (b) TNF- α and (d) IL-6. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (e) TNF- α and (g) IL-6. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (f) TNF- α and (h) IL-6. Concentrations of TNF- α and IL-6 in the culture supernatants were determined by ELISA. White column: STEMI; black column: post-STEMI; n = 11. ∗ p

    Techniques Used: Positive Control, Negative Control, Enzyme-linked Immunosorbent Assay

    Monocytes transmigrate across a human umbilical vein endothelial cell monolayer in response to IL-17. A sample of 3 × 10 5 (a–c) CD14 ++ CD16 − or (d–f) CD14 ++ CD16 + /CD14 + CD16 ++ monocytes was added to the upper surface of monolayers of human umbilical vein endothelial cells (HUVECs) previously treated with IL-17, IFN- γ , or IL-17/IFN- γ ; culture medium alone was used as a negative control. The monocytes were allowed to transmigrate across the HUVEC monolayers in the presence of CCL2, CX3CL1, or culture medium for 3 hours. All data are presented as the migration index, which relates the number of cells that migrated in response to the indicated stimulus to the number of cells that migrated in response to the negative control. White column: STEMI: black column: post-STEMI; n = 11. ∗ p
    Figure Legend Snippet: Monocytes transmigrate across a human umbilical vein endothelial cell monolayer in response to IL-17. A sample of 3 × 10 5 (a–c) CD14 ++ CD16 − or (d–f) CD14 ++ CD16 + /CD14 + CD16 ++ monocytes was added to the upper surface of monolayers of human umbilical vein endothelial cells (HUVECs) previously treated with IL-17, IFN- γ , or IL-17/IFN- γ ; culture medium alone was used as a negative control. The monocytes were allowed to transmigrate across the HUVEC monolayers in the presence of CCL2, CX3CL1, or culture medium for 3 hours. All data are presented as the migration index, which relates the number of cells that migrated in response to the indicated stimulus to the number of cells that migrated in response to the negative control. White column: STEMI: black column: post-STEMI; n = 11. ∗ p

    Techniques Used: Negative Control, Migration

    Related Articles

    Activation Assay:

    Article Title: Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans
    Article Snippet: Finally, cells were stained with anti-IFN-γ and anti-IL-2 for 30 min on ice, washed, and fixed with 1% formaldehyde before acquisition on a FACS Canto flow cytometer. .. For analysis of anti-virus-specific CD8 T activation in vitro , freshly isolated PBMC or purified CD8+ T cells were incubated in vitro at 2×106 /ml with or without cytokines (IL-7, IL-2, IL-15, IFN-γ, IFN- α, TNF- α, purchased from RnD Systems, Minneapolis, MN). .. The cells were collected at indicated time points, and the intracellular cytokine staining was performed as described above.

    In Vitro:

    Article Title: Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans
    Article Snippet: Finally, cells were stained with anti-IFN-γ and anti-IL-2 for 30 min on ice, washed, and fixed with 1% formaldehyde before acquisition on a FACS Canto flow cytometer. .. For analysis of anti-virus-specific CD8 T activation in vitro , freshly isolated PBMC or purified CD8+ T cells were incubated in vitro at 2×106 /ml with or without cytokines (IL-7, IL-2, IL-15, IFN-γ, IFN- α, TNF- α, purchased from RnD Systems, Minneapolis, MN). .. The cells were collected at indicated time points, and the intracellular cytokine staining was performed as described above.

    Isolation:

    Article Title: Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans
    Article Snippet: Finally, cells were stained with anti-IFN-γ and anti-IL-2 for 30 min on ice, washed, and fixed with 1% formaldehyde before acquisition on a FACS Canto flow cytometer. .. For analysis of anti-virus-specific CD8 T activation in vitro , freshly isolated PBMC or purified CD8+ T cells were incubated in vitro at 2×106 /ml with or without cytokines (IL-7, IL-2, IL-15, IFN-γ, IFN- α, TNF- α, purchased from RnD Systems, Minneapolis, MN). .. The cells were collected at indicated time points, and the intracellular cytokine staining was performed as described above.

    Purification:

    Article Title: Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans
    Article Snippet: Finally, cells were stained with anti-IFN-γ and anti-IL-2 for 30 min on ice, washed, and fixed with 1% formaldehyde before acquisition on a FACS Canto flow cytometer. .. For analysis of anti-virus-specific CD8 T activation in vitro , freshly isolated PBMC or purified CD8+ T cells were incubated in vitro at 2×106 /ml with or without cytokines (IL-7, IL-2, IL-15, IFN-γ, IFN- α, TNF- α, purchased from RnD Systems, Minneapolis, MN). .. The cells were collected at indicated time points, and the intracellular cytokine staining was performed as described above.

    Incubation:

    Article Title: Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans
    Article Snippet: Finally, cells were stained with anti-IFN-γ and anti-IL-2 for 30 min on ice, washed, and fixed with 1% formaldehyde before acquisition on a FACS Canto flow cytometer. .. For analysis of anti-virus-specific CD8 T activation in vitro , freshly isolated PBMC or purified CD8+ T cells were incubated in vitro at 2×106 /ml with or without cytokines (IL-7, IL-2, IL-15, IFN-γ, IFN- α, TNF- α, purchased from RnD Systems, Minneapolis, MN). .. The cells were collected at indicated time points, and the intracellular cytokine staining was performed as described above.

    Article Title: miR-155 in the progression of lung fibrosis in systemic sclerosis
    Article Snippet: Lung fibroblasts were cultured in DMEM supplemented with 10 % fetal bovine serum and penicillin/streptomycin and utilized at passages 2–4. .. Fibroblasts (100 % confluent) were incubated in serum-free DMEM overnight prior to stimulation with TGFß (R & D System; 2.5 ng/ml), recombinant human IL-13 (R & D Systems, 20 ng/ml), or interferon-alpha (IFN) (R & D Systems; 500 U/ml) for 18 hours. .. Total RNA from fibroblasts was transferred in Qiazol buffer and purified using the miRNease mini kit protocol (Qiagen).

    Recombinant:

    Article Title: Molecular Signatures Associated with Mx1-Mediated Resistance to Highly Pathogenic Influenza Virus Infection: Mechanisms of Survival
    Article Snippet: .. In addition, half of the animals were intranasally treated with 10,000 units of recombinant human alpha interferon (IFN-α) A/D (R & D Systems, Minneapolis, MN) before infection with the reconstructed 1918 virus and euthanized 12, 24, and 72 h posttreatment. ..

    Article Title: miR-155 in the progression of lung fibrosis in systemic sclerosis
    Article Snippet: Lung fibroblasts were cultured in DMEM supplemented with 10 % fetal bovine serum and penicillin/streptomycin and utilized at passages 2–4. .. Fibroblasts (100 % confluent) were incubated in serum-free DMEM overnight prior to stimulation with TGFß (R & D System; 2.5 ng/ml), recombinant human IL-13 (R & D Systems, 20 ng/ml), or interferon-alpha (IFN) (R & D Systems; 500 U/ml) for 18 hours. .. Total RNA from fibroblasts was transferred in Qiazol buffer and purified using the miRNease mini kit protocol (Qiagen).

    Article Title: HIV envelope gp120 activates human arterial smooth muscle cells
    Article Snippet: These results provide evidence for direct viral activation of human SMC and may provide insight into the mechanism underlying the increased incidence of acute coronary syndromes and prothrombotic states in patients with HIV. .. Recombinant human macrophage inflammatory protein-1β (MIP-1), platelet-derived growth factor, recombinant human IL-16, recombinant human stromal cell-derived growth factor 1-α (SDF-1), and monoclonal antibodies to human CXCR4 and CCR5 were from R & D Systems. .. FBS, 8-bromoadenosine 3′:5′-cyclic monophosphate sodium (Tiron), actinomycin D, phorbol 12,13-dibutyrate, a monoclonal anti-human CD4 antibody, clone Q4120, and its isotype-matched IgG control were from Sigma.

    Infection:

    Article Title: Molecular Signatures Associated with Mx1-Mediated Resistance to Highly Pathogenic Influenza Virus Infection: Mechanisms of Survival
    Article Snippet: .. In addition, half of the animals were intranasally treated with 10,000 units of recombinant human alpha interferon (IFN-α) A/D (R & D Systems, Minneapolis, MN) before infection with the reconstructed 1918 virus and euthanized 12, 24, and 72 h posttreatment. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    R&D Systems il 17 ifn γ
    Expression of surface markers on monocytes stimulated with <t>IL-17.</t> Human CD14 ++ CD16 − and CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TLR4, (e) CD86, and (i) HLA-DR. Human CD14 ++ CD16 − in post-STEMI: (b) TLR4, (f) CD86, and (j) HLA-DR. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (c) TLR4, (g) CD86, and (k) HLA-DR. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (d) TLR4, (h) CD86, and (l) HLA-DR. Expression levels of TLR4, CD86, and HLA-DR are expressed as MFI. White column: STEMI; black column: post-STEMI; n = 11. ∗ p
    Il 17 Ifn γ, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il 17 ifn γ/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    il 17 ifn γ - by Bioz Stars, 2021-06
    94/100 stars
      Buy from Supplier

    99
    R&D Systems multiple cytokine analysis kits
    Age-related changes of CT score, neutrophils and neutrophil-associated <t>cytokine</t> in the subtype of nasal polyps. (A) CT score (n = 80). (B) Comparison of CT score among age groups in NE-NP (n = 37, ** P
    Multiple Cytokine Analysis Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/multiple cytokine analysis kits/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    multiple cytokine analysis kits - by Bioz Stars, 2021-06
    99/100 stars
      Buy from Supplier

    99
    R&D Systems elispot assaysdual color elispot mouse ifn γ il 17 kits
    Graphs of ELISspot disk counts comparing vaccinations of our TF-MUC4 B13G AuNP conjugate the TF-MUC4-CRM197 conjugate and control B13G AuNPs when panned for interferon-γ and <t>IL-17</t> production. While the CRM197 conjugate has an intense humoral response, the TF-MUC4 vaccine construct elicited a much stronger CD4 + T-cell response, whereas the control AuNPs consistently showed no response.
    Elispot Assaysdual Color Elispot Mouse Ifn γ Il 17 Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elispot assaysdual color elispot mouse ifn γ il 17 kits/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    elispot assaysdual color elispot mouse ifn γ il 17 kits - by Bioz Stars, 2021-06
    99/100 stars
      Buy from Supplier

    99
    R&D Systems elisa kits
    HC-HA/PTX3 downregulates <t>IFN-γ,</t> IL-2 production and CD4 + /CD69 + , CD4 + /CD25 + expression. Splenocytes were treated with or without 25 μg/mL HA, AME, or HC-HA/PTX3 and stimulated with 0 to 10 μM OVA peptide 323-339 for 4 days. The culturing medium was subjected to the respective <t>ELISA</t> for IFN-γ ( A ) and IL-2 ( B ). Cells were analyzed with flow cytometry with CD4 antibody combined with CD69 antibody ( C ) or with CD25 antibody ( D ). n = 3; * P
    Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elisa kits/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    elisa kits - by Bioz Stars, 2021-06
    99/100 stars
      Buy from Supplier

    Image Search Results


    Expression of surface markers on monocytes stimulated with IL-17. Human CD14 ++ CD16 − and CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TLR4, (e) CD86, and (i) HLA-DR. Human CD14 ++ CD16 − in post-STEMI: (b) TLR4, (f) CD86, and (j) HLA-DR. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (c) TLR4, (g) CD86, and (k) HLA-DR. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (d) TLR4, (h) CD86, and (l) HLA-DR. Expression levels of TLR4, CD86, and HLA-DR are expressed as MFI. White column: STEMI; black column: post-STEMI; n = 11. ∗ p

    Journal: Journal of Immunology Research

    Article Title: Effect of Interleukin-17 in the Activation of Monocyte Subsets in Patients with ST-Segment Elevation Myocardial Infarction

    doi: 10.1155/2020/5692829

    Figure Lengend Snippet: Expression of surface markers on monocytes stimulated with IL-17. Human CD14 ++ CD16 − and CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TLR4, (e) CD86, and (i) HLA-DR. Human CD14 ++ CD16 − in post-STEMI: (b) TLR4, (f) CD86, and (j) HLA-DR. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (c) TLR4, (g) CD86, and (k) HLA-DR. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (d) TLR4, (h) CD86, and (l) HLA-DR. Expression levels of TLR4, CD86, and HLA-DR are expressed as MFI. White column: STEMI; black column: post-STEMI; n = 11. ∗ p

    Article Snippet: The HUVECs were activated for 1 day with IL-17 (60 ng/ml), interferon- (IFN-) γ (25 ng/ml), which was used as an inhibitory control for monocyte migration, or IL-17/IFN-γ (R & D Systems, Minnesota, USA), and culture medium alone was used as a negative control.

    Techniques: Expressing, Positive Control, Negative Control

    IL-17 induces the secretion of proinflammatory cytokines in monocyte subsets. Human CD14 ++ CD16 − or CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TNF- α and (c) IL-6. Human CD14 ++ CD16 − in post-STEMI: (b) TNF- α and (d) IL-6. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (e) TNF- α and (g) IL-6. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (f) TNF- α and (h) IL-6. Concentrations of TNF- α and IL-6 in the culture supernatants were determined by ELISA. White column: STEMI; black column: post-STEMI; n = 11. ∗ p

    Journal: Journal of Immunology Research

    Article Title: Effect of Interleukin-17 in the Activation of Monocyte Subsets in Patients with ST-Segment Elevation Myocardial Infarction

    doi: 10.1155/2020/5692829

    Figure Lengend Snippet: IL-17 induces the secretion of proinflammatory cytokines in monocyte subsets. Human CD14 ++ CD16 − or CD14 ++ CD16 + /CD14 + CD16 ++ monocytes were treated with IL-17, IFN- γ , which was used as a positive control, IL-17/IFN- γ , or culture medium alone, which was used as a negative control, for 24 hours. Human CD14 ++ CD16 − in STEMI: (a) TNF- α and (c) IL-6. Human CD14 ++ CD16 − in post-STEMI: (b) TNF- α and (d) IL-6. Human CD14 ++ CD16 + /CD14 + CD16 ++ monocytes in STEMI: (e) TNF- α and (g) IL-6. CD14 ++ CD16 + /CD14 + CD16 ++ monocytes post-STEMI: (f) TNF- α and (h) IL-6. Concentrations of TNF- α and IL-6 in the culture supernatants were determined by ELISA. White column: STEMI; black column: post-STEMI; n = 11. ∗ p

    Article Snippet: The HUVECs were activated for 1 day with IL-17 (60 ng/ml), interferon- (IFN-) γ (25 ng/ml), which was used as an inhibitory control for monocyte migration, or IL-17/IFN-γ (R & D Systems, Minnesota, USA), and culture medium alone was used as a negative control.

    Techniques: Positive Control, Negative Control, Enzyme-linked Immunosorbent Assay

    Monocytes transmigrate across a human umbilical vein endothelial cell monolayer in response to IL-17. A sample of 3 × 10 5 (a–c) CD14 ++ CD16 − or (d–f) CD14 ++ CD16 + /CD14 + CD16 ++ monocytes was added to the upper surface of monolayers of human umbilical vein endothelial cells (HUVECs) previously treated with IL-17, IFN- γ , or IL-17/IFN- γ ; culture medium alone was used as a negative control. The monocytes were allowed to transmigrate across the HUVEC monolayers in the presence of CCL2, CX3CL1, or culture medium for 3 hours. All data are presented as the migration index, which relates the number of cells that migrated in response to the indicated stimulus to the number of cells that migrated in response to the negative control. White column: STEMI: black column: post-STEMI; n = 11. ∗ p

    Journal: Journal of Immunology Research

    Article Title: Effect of Interleukin-17 in the Activation of Monocyte Subsets in Patients with ST-Segment Elevation Myocardial Infarction

    doi: 10.1155/2020/5692829

    Figure Lengend Snippet: Monocytes transmigrate across a human umbilical vein endothelial cell monolayer in response to IL-17. A sample of 3 × 10 5 (a–c) CD14 ++ CD16 − or (d–f) CD14 ++ CD16 + /CD14 + CD16 ++ monocytes was added to the upper surface of monolayers of human umbilical vein endothelial cells (HUVECs) previously treated with IL-17, IFN- γ , or IL-17/IFN- γ ; culture medium alone was used as a negative control. The monocytes were allowed to transmigrate across the HUVEC monolayers in the presence of CCL2, CX3CL1, or culture medium for 3 hours. All data are presented as the migration index, which relates the number of cells that migrated in response to the indicated stimulus to the number of cells that migrated in response to the negative control. White column: STEMI: black column: post-STEMI; n = 11. ∗ p

    Article Snippet: The HUVECs were activated for 1 day with IL-17 (60 ng/ml), interferon- (IFN-) γ (25 ng/ml), which was used as an inhibitory control for monocyte migration, or IL-17/IFN-γ (R & D Systems, Minnesota, USA), and culture medium alone was used as a negative control.

    Techniques: Negative Control, Migration

    Age-related changes of CT score, neutrophils and neutrophil-associated cytokine in the subtype of nasal polyps. (A) CT score (n = 80). (B) Comparison of CT score among age groups in NE-NP (n = 37, ** P

    Journal: PLoS ONE

    Article Title: Age-Related Decline of Neutrophilic Inflammation Is Associated with Better Postoperative Prognosis in Non-eosinophilic Nasal Polyps

    doi: 10.1371/journal.pone.0148442

    Figure Lengend Snippet: Age-related changes of CT score, neutrophils and neutrophil-associated cytokine in the subtype of nasal polyps. (A) CT score (n = 80). (B) Comparison of CT score among age groups in NE-NP (n = 37, ** P

    Article Snippet: Multiple cytokine analysis kits (IL-5, IL-17A, IL-23, IFN-γ, CXCL-8, and CCL-11) were obtained from R & D systems (Cat. No. LMSAHM) and data were collected using Luminex 100 (Luminex, Austin, TX, USA).

    Techniques:

    Graphs of ELISspot disk counts comparing vaccinations of our TF-MUC4 B13G AuNP conjugate the TF-MUC4-CRM197 conjugate and control B13G AuNPs when panned for interferon-γ and IL-17 production. While the CRM197 conjugate has an intense humoral response, the TF-MUC4 vaccine construct elicited a much stronger CD4 + T-cell response, whereas the control AuNPs consistently showed no response.

    Journal: bioRxiv

    Article Title: A Stable Nano-Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens

    doi: 10.1101/2021.04.27.438445

    Figure Lengend Snippet: Graphs of ELISspot disk counts comparing vaccinations of our TF-MUC4 B13G AuNP conjugate the TF-MUC4-CRM197 conjugate and control B13G AuNPs when panned for interferon-γ and IL-17 production. While the CRM197 conjugate has an intense humoral response, the TF-MUC4 vaccine construct elicited a much stronger CD4 + T-cell response, whereas the control AuNPs consistently showed no response.

    Article Snippet: ELISpot assaysDual-Color ELISpot Mouse IFN-γ/IL-17 kits (R & D systems catalog #ELD5007) were used and the assays were performed using the manufacturers protocols.

    Techniques: Construct

    HC-HA/PTX3 downregulates IFN-γ, IL-2 production and CD4 + /CD69 + , CD4 + /CD25 + expression. Splenocytes were treated with or without 25 μg/mL HA, AME, or HC-HA/PTX3 and stimulated with 0 to 10 μM OVA peptide 323-339 for 4 days. The culturing medium was subjected to the respective ELISA for IFN-γ ( A ) and IL-2 ( B ). Cells were analyzed with flow cytometry with CD4 antibody combined with CD69 antibody ( C ) or with CD25 antibody ( D ). n = 3; * P

    Journal: Investigative Ophthalmology & Visual Science

    Article Title: In Vivo Downregulation of Innate and Adaptive Immune Responses in Corneal Allograft Rejection by HC-HA/PTX3 Complex Purified From Amniotic Membrane

    doi: 10.1167/iovs.13-13094

    Figure Lengend Snippet: HC-HA/PTX3 downregulates IFN-γ, IL-2 production and CD4 + /CD69 + , CD4 + /CD25 + expression. Splenocytes were treated with or without 25 μg/mL HA, AME, or HC-HA/PTX3 and stimulated with 0 to 10 μM OVA peptide 323-339 for 4 days. The culturing medium was subjected to the respective ELISA for IFN-γ ( A ) and IL-2 ( B ). Cells were analyzed with flow cytometry with CD4 antibody combined with CD69 antibody ( C ) or with CD25 antibody ( D ). n = 3; * P

    Article Snippet: Murine recombinant proteins (IFN-γ and IL-4) and ELISA kits (murine IFN-γ, IL-2, and IL-17) were from R & D Systems (Minneapolis, MN), and the other ELISA kits (murine IL-10, IL-12, and IL-23) were from Biolegend (San Diego, CA).

    Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Cytometry

    HC-HA/PTX3 upregulates IL-10 but downregulates IL-12 and IL-23 in IFN-γ/LPS-stimulated macrophages. RAW264.7 cells on immobilized PBS, HA, or HC-HA/PTX3 were stimulated with IFN-γ/LPS for 24 hours. IL-10 ( A ) and IL-12p40 ( B ) in cell supernatants were determined by respective ELISA ( n = 3). RAW264.7 cells on immobilized PBS, HA, or HC-HA/PTX3 were stimulated with IFN-γ, LPS, IFN-γ/LPS, LPS/IC, or IL-4 for 24 hours. IL-23 in cell supernatants was determined by ELISA ( n = 3) ( C ). IL-23 ELISA was determined as in C , except cells were stimulated with IFN-γ/LPS ( n = 3) ( D ). * P

    Journal: Investigative Ophthalmology & Visual Science

    Article Title: In Vivo Downregulation of Innate and Adaptive Immune Responses in Corneal Allograft Rejection by HC-HA/PTX3 Complex Purified From Amniotic Membrane

    doi: 10.1167/iovs.13-13094

    Figure Lengend Snippet: HC-HA/PTX3 upregulates IL-10 but downregulates IL-12 and IL-23 in IFN-γ/LPS-stimulated macrophages. RAW264.7 cells on immobilized PBS, HA, or HC-HA/PTX3 were stimulated with IFN-γ/LPS for 24 hours. IL-10 ( A ) and IL-12p40 ( B ) in cell supernatants were determined by respective ELISA ( n = 3). RAW264.7 cells on immobilized PBS, HA, or HC-HA/PTX3 were stimulated with IFN-γ, LPS, IFN-γ/LPS, LPS/IC, or IL-4 for 24 hours. IL-23 in cell supernatants was determined by ELISA ( n = 3) ( C ). IL-23 ELISA was determined as in C , except cells were stimulated with IFN-γ/LPS ( n = 3) ( D ). * P

    Article Snippet: Murine recombinant proteins (IFN-γ and IL-4) and ELISA kits (murine IFN-γ, IL-2, and IL-17) were from R & D Systems (Minneapolis, MN), and the other ELISA kits (murine IL-10, IL-12, and IL-23) were from Biolegend (San Diego, CA).

    Techniques: Enzyme-linked Immunosorbent Assay

    HC-HA/PTX3 directly inhibits activation of purified CD4 + T cell. CD4 + T cells were isolated from cell suspensions of lymph nodes and spleens from 4- to 8-week-old C57BL/6 mice. Purified CD4 + T cells (at 1 × 10 6 cells/mL) were costimulated with 1 μg/mL α-CD3/α-CD28 and treated with or without 25 μg/mL HA or HC-HA/PTX3 for 48 hours in 12-well plates coated with anti-hamster IgG. CD4 + T-cell activation was analyzed by flow cytometry with specific antibodies to CD4, CD69, and Ki67 ( A ), and CD4, CD25, and FOXP3 ( B ), as well as ELISA of IFN-γ ( C ), IL-2 ( D ), and IL-17 ( E ). In addition, ELISA of IL-17 was also performed on OVA peptide-stimulated splenocytes ( F ). n = 3; * P

    Journal: Investigative Ophthalmology & Visual Science

    Article Title: In Vivo Downregulation of Innate and Adaptive Immune Responses in Corneal Allograft Rejection by HC-HA/PTX3 Complex Purified From Amniotic Membrane

    doi: 10.1167/iovs.13-13094

    Figure Lengend Snippet: HC-HA/PTX3 directly inhibits activation of purified CD4 + T cell. CD4 + T cells were isolated from cell suspensions of lymph nodes and spleens from 4- to 8-week-old C57BL/6 mice. Purified CD4 + T cells (at 1 × 10 6 cells/mL) were costimulated with 1 μg/mL α-CD3/α-CD28 and treated with or without 25 μg/mL HA or HC-HA/PTX3 for 48 hours in 12-well plates coated with anti-hamster IgG. CD4 + T-cell activation was analyzed by flow cytometry with specific antibodies to CD4, CD69, and Ki67 ( A ), and CD4, CD25, and FOXP3 ( B ), as well as ELISA of IFN-γ ( C ), IL-2 ( D ), and IL-17 ( E ). In addition, ELISA of IL-17 was also performed on OVA peptide-stimulated splenocytes ( F ). n = 3; * P

    Article Snippet: Murine recombinant proteins (IFN-γ and IL-4) and ELISA kits (murine IFN-γ, IL-2, and IL-17) were from R & D Systems (Minneapolis, MN), and the other ELISA kits (murine IL-10, IL-12, and IL-23) were from Biolegend (San Diego, CA).

    Techniques: Activation Assay, Purification, Isolation, Mouse Assay, Flow Cytometry, Cytometry, Enzyme-linked Immunosorbent Assay

    HC-HA/PTX3 inhibits CD4 + T-cell proliferation. Splenocytes isolated from OVA T-cell receptor transgenic mice were cultivated at DMEM/10% FBS and stimulated by a nonspecific HY peptide (NAGFNSNRANSSRSS, 10 μM) or OVA peptide 323-339 (ISQAVHAAHAEINEAGR, 0−10 μM) for 4 days before flow cytometry with specific antibodies to CD4, CD69, and Ki67, and ELISA of IFN-γ, IL-2, and IL-17 ( n = 3) ( A ). Subsequently, splenocytes were treated with or without 25 μg/mL HA, AME, or HC-HA/PTX3 and stimulated with OVA peptide 323-339 (0−10 μM) for 4 days. Cells were labeled with BrdU (10 μM) during the last 12 hours of the cell cultivation and CD4 + T-cell proliferation was analyzed similar to A ( n = 3) ( B ). Alternatively, splenocytes were treated with a serial of concentrations (0, 0.04, 0.2, 1, 5, and 25 μg/mL) of HA, AME, or HC-HA/PTX3 and stimulated with 10 μM OVA peptide 323-339 for 4 days, and CD4 + T-cell proliferation was determined by flow cytometry ( n = 3) ( C ).

    Journal: Investigative Ophthalmology & Visual Science

    Article Title: In Vivo Downregulation of Innate and Adaptive Immune Responses in Corneal Allograft Rejection by HC-HA/PTX3 Complex Purified From Amniotic Membrane

    doi: 10.1167/iovs.13-13094

    Figure Lengend Snippet: HC-HA/PTX3 inhibits CD4 + T-cell proliferation. Splenocytes isolated from OVA T-cell receptor transgenic mice were cultivated at DMEM/10% FBS and stimulated by a nonspecific HY peptide (NAGFNSNRANSSRSS, 10 μM) or OVA peptide 323-339 (ISQAVHAAHAEINEAGR, 0−10 μM) for 4 days before flow cytometry with specific antibodies to CD4, CD69, and Ki67, and ELISA of IFN-γ, IL-2, and IL-17 ( n = 3) ( A ). Subsequently, splenocytes were treated with or without 25 μg/mL HA, AME, or HC-HA/PTX3 and stimulated with OVA peptide 323-339 (0−10 μM) for 4 days. Cells were labeled with BrdU (10 μM) during the last 12 hours of the cell cultivation and CD4 + T-cell proliferation was analyzed similar to A ( n = 3) ( B ). Alternatively, splenocytes were treated with a serial of concentrations (0, 0.04, 0.2, 1, 5, and 25 μg/mL) of HA, AME, or HC-HA/PTX3 and stimulated with 10 μM OVA peptide 323-339 for 4 days, and CD4 + T-cell proliferation was determined by flow cytometry ( n = 3) ( C ).

    Article Snippet: Murine recombinant proteins (IFN-γ and IL-4) and ELISA kits (murine IFN-γ, IL-2, and IL-17) were from R & D Systems (Minneapolis, MN), and the other ELISA kits (murine IL-10, IL-12, and IL-23) were from Biolegend (San Diego, CA).

    Techniques: Isolation, Transgenic Assay, Mouse Assay, Flow Cytometry, Cytometry, Enzyme-linked Immunosorbent Assay, Labeling